Peringatan Keamanan

There is limited information regarding the acute toxicity (LD50) and overdosage of donanemab.

Donanemab

DB16647

biotech approved investigational

Deskripsi

Donanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta (A?), L50978 which is found in the brain amyloid plaques that contribute to the pathophysiology of Alzheimer's Disease (AD).A232214 On July 2, 2024, donanemab was approved by the FDA for the treatment of AD in patients with mild cognitive impairment or dementia symptoms.L50988 It works to reduce amyloid beta plaques and impede the progression of AD.L50988

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean terminal half-life of donanemab is approximately 12.1 days.[L50988]
Volume Distribusi The central volume of distribution is 3.36 L.[L50988]
Klirens (Clearance) The clearance is about 0.0255 L/h.[L50988]

Absorpsi

In patients with AD, drug accumulation of <1.3-fold occurs with every 4-week dosing. Steady-state exposures are achieved after a single dose. In single doses from 10 to 40 mg/kg (~2 times the approved recommended dosage of 1400 mg for 70 kg of body weight), and multiple 10 and 20 mg/kg doses, exposures (Cmax and AUC) increased proportionally.L50988

Metabolisme

Donanemab is expected to be degraded by proteolytic enzymes in the same manner as endogenous IgG.L50988

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Donanemab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Donanemab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Donanemab.
Estrone Estrone may increase the thrombogenic activities of Donanemab.
Estradiol Estradiol may increase the thrombogenic activities of Donanemab.
Dienestrol Dienestrol may increase the thrombogenic activities of Donanemab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Donanemab.
Mestranol Mestranol may increase the thrombogenic activities of Donanemab.
Estriol Estriol may increase the thrombogenic activities of Donanemab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Donanemab.
Quinestrol Quinestrol may increase the thrombogenic activities of Donanemab.
Hexestrol Hexestrol may increase the thrombogenic activities of Donanemab.
Tibolone Tibolone may increase the thrombogenic activities of Donanemab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Donanemab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Donanemab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Donanemab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Donanemab.
Zeranol Zeranol may increase the thrombogenic activities of Donanemab.
Equol Equol may increase the thrombogenic activities of Donanemab.
Estetrol Estetrol may increase the thrombogenic activities of Donanemab.
Promestriene Promestriene may increase the thrombogenic activities of Donanemab.
Methallenestril Methallenestril may increase the thrombogenic activities of Donanemab.
Epimestrol Epimestrol may increase the thrombogenic activities of Donanemab.
Moxestrol Moxestrol may increase the thrombogenic activities of Donanemab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Donanemab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Donanemab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Donanemab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Donanemab.
Biochanin A Biochanin A may increase the thrombogenic activities of Donanemab.
Formononetin Formononetin may increase the thrombogenic activities of Donanemab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Donanemab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Donanemab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Donanemab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Donanemab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Donanemab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Donanemab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Donanemab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Donanemab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Donanemab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Donanemab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Donanemab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Donanemab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Donanemab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Donanemab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Donanemab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Donanemab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Donanemab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Donanemab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Donanemab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Donanemab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Donanemab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Donanemab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Donanemab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Donanemab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Donanemab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Donanemab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Donanemab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Donanemab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Donanemab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Donanemab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Donanemab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Donanemab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Donanemab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Donanemab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Donanemab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Donanemab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Donanemab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Donanemab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Donanemab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Donanemab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Donanemab.
Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Donanemab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Donanemab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Donanemab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Donanemab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Donanemab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Donanemab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Donanemab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Donanemab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Donanemab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Donanemab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Donanemab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Donanemab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Donanemab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Donanemab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Donanemab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Donanemab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Donanemab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Donanemab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Donanemab.
Stamulumab The risk or severity of adverse effects can be increased when Stamulumab is combined with Donanemab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Donanemab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Donanemab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Donanemab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Donanemab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Donanemab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Donanemab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Donanemab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Donanemab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Donanemab.

Target Protein

Beta amyloid plaque

Referensi & Sumber

Artikel (PubMed)
  • PMID: 33614890
    Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, Shcherbinin S, Ardayfio P, Sims JR: Donanemab (LY3002813) dose-escalation study in Alzheimer's disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. doi: 10.1002/trc2.12112. eCollection 2021.
  • PMID: 37459141
    Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM: Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
  • PMID: 28261941
    Takahashi RH, Nagao T, Gouras GK: Plaque formation and the intraneuronal accumulation of beta-amyloid in Alzheimer's disease. Pathol Int. 2017 Apr;67(4):185-193. doi: 10.1111/pin.12520. Epub 2017 Mar 5.
  • PMID: 36611492
    Rashad A, Rasool A, Shaheryar M, Sarfraz A, Sarfraz Z, Robles-Velasco K, Cherrez-Ojeda I: Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials. Healthcare (Basel). 2022 Dec 22;11(1):32. doi: 10.3390/healthcare11010032.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Kisunla
    Injection, solution • 17.5 mg/1mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul